These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 10048477)
1. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy. Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR; J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312 [TBL] [Abstract][Full Text] [Related]
4. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854 [TBL] [Abstract][Full Text] [Related]
5. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study. Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849 [TBL] [Abstract][Full Text] [Related]
8. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial. Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P; Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935 [TBL] [Abstract][Full Text] [Related]
10. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706 [TBL] [Abstract][Full Text] [Related]
11. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679 [TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387 [TBL] [Abstract][Full Text] [Related]
13. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Gridelli C; Gallo C; Ceribelli A; Gebbia V; Gamucci T; Ciardiello F; Carozza F; Favaretto A; Daniele B; Galetta D; Barbera S; Rosetti F; Rossi A; Maione P; Cognetti F; Testa A; Di Maio M; Morabito A; Perrone F; Lancet Oncol; 2007 Jun; 8(6):500-12. PubMed ID: 17513173 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603 [TBL] [Abstract][Full Text] [Related]
16. First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule. Quoix E; Breton JL; Ducoloné A; Mennecier B; Depierre A; Lemarié E; Moro-Sibilot D; Germa C; Neidhardt AC Lung Cancer; 2005 Mar; 47(3):405-12. PubMed ID: 15713524 [TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Cho KH; Song YB; Choi IS; Cho EH; Choi JW; Ahn YM; Roh YH; Nam SH; Kim BS Jpn J Clin Oncol; 2006 Jan; 36(1):50-4. PubMed ID: 16418187 [TBL] [Abstract][Full Text] [Related]
19. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158 [TBL] [Abstract][Full Text] [Related]
20. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Gridelli C; De Maio E; Barbera S; Sannicolo M; Piazza E; Piantedosi F; Brancaccio L; Morabito A; Maione P; Renda F; Signoriello G; Perrone F; Lung Cancer; 2008 Jul; 61(1):67-72. PubMed ID: 18683299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]